|
A healthcare professional reported that 1 ml of juvéderm® voluma¿ xc in the chin, 0.5 ml of juvéderm® volbella¿ xc in the lips, and 1 ml of juvéderm® ultra xc.The patient experienced one large, delayed onset nodules on both sides of chin, two small, delayed onset nodules on the left lower lip, and three small, delayed onset nodules on the left upper lip.Recently the hcp reported performing a physical examination and treating patient with 5-fu.This was the initial use of the syringe.An additional follow-up will be provided.Symptoms are ongoing.Additionally, the patient reported an adverse event with an unspecified juvéderm® xc product and stated that a healthcare professional was asked to evaluate the lumps.The patient reported four areas of delayed-onset granulomas on the face following treatment approximately five months earlier, involving the upper lip, lower lip, and chin.The patient¿s lips were injected with juvéderm volbella® xc, and the chin was injected with juvéderm voluma® xc.The hcp injected a product to help reduce swelling, and the patient was also prescribed zyrtec and pepcid.
|
|
Clarification to h.6.Type of investigation code: the filler was injected into the patient and is not accessible for return.The syringe was not returned for evaluation.The event is a physiological complication and analysis of the device generally does not assist abbvie in determining a probable cause for this event.Further information regarding event, product, or patient details has been requested.No additional information is available at this time.A review of the device history record has been initiated.If any new, changed or corrected information is noted, a supplemental medwatch will be submitted.This is a known potential adverse event addressed in the product labeling.
|